Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec;178(23):4588-4607.
doi: 10.1111/bph.15657. Epub 2021 Sep 26.

Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments

Farzin Zobdeh  1   2 , Aziza Ben Kraiem  1   2 , Misty M Attwood  2 , Vladimir N Chubarev  1 , Vadim V Tarasov  1   3 , Helgi B Schiöth  2   3 , Jessica Mwinyi  2
Affiliations
Free article
Review

Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments

Farzin Zobdeh et al. Br J Pharmacol. 2021 Dec.
Free article

Abstract

Migraine is the sixth most prevalent disease globally, a major cause of disability, and it imposes an enormous personal and socio-economic burden. Migraine treatment is often limited by insufficient therapy response, leading to the need for individually adjusted treatment. In this review, we analyse historical and current pharmaceutical development approaches in acute and chronic migraine based on a comprehensive and systematic analysis of Food and Drug Administration (FDA)-approved drugs and those under investigation. The development of migraine therapeutics has significantly intensified during the last 3 years, as shown by our analysis of the trends of drug development between 1970 and 2020. The spectrum of drug targets has expanded considerably, which has been accompanied by an increase in the number of specialised clinical trials. This review highlights the mechanistic implications of FDA-approved and currently investigated drugs and discusses current and future therapeutic options based on identified drug classes of interest.

Keywords: 5-HT; CGRP; clinical trials; migraine; migraine acute treatment; migraine chronic treatment.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Ailani, J., Lipton, R. B., Hutchinson, S., Knievel, K., Lu, K., Butler, M., Yu, S. Y., Finnegan, M., Severt, L., & Trugman, J. M. (2020). Long-term safety evaluation of ubrogepant for the acute treatment of migraine: Phase 3, randomized, 52-week extension trial. Headache, 60(1), 141-152. https://doi.org/10.1111/head.13682
    1. Akerman, S., & Goadsby, P. J. (2005). Topiramate inhibits trigeminovascular activation: An intravital microscopy study. British Journal of Pharmacology, 146(1), 7-14. https://doi.org/10.1038/sj.bjp.0706290
    1. Akopian, A. N., Chen, C. C., Ding, Y., Cesare, P., & Wood, J. N. (2000). A new member of the acid-sensing ion channel family. Neuroreport, 11(10), 2217-2222. https://doi.org/10.1097/00001756-200007140-00031
    1. Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., & Pawson, A. J. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 176, S21-S141. https://doi.org/10.1111/bph.14748
    1. Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., & Southan, C. (2019). THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes. British Journal of Pharmacology, 176, S297-S396. https://doi.org/10.1111/bph.14752

Publication types

Substances